

## Drug and Therapeutics Committee – Minutes

<b>Date / Time</b>	November 10 <sup>th</sup> 2022
<b>Venue</b>	WebEx
<b>Chair</b>	Prof A Morice, Chair, Professor of Respiratory Medicine
<b>Notes / Action Points</b>	Luke Storr – Senior Pharmacy Technician, Formulary HUTH
<b>Quorate: Yes / No</b>	Yes

<b>Attendance</b>	Prof A Morice, Chair, Professor of Respiratory Medicine Mr K McCorry, Medicines Optimisation Pharmacist, NECS Miss J Morgan, Professional Secretary, Principal Pharmacist – Formulary HUTH Mr P O'Brien, Deputy Chief Pharmacist, HUTH Dr H Klonin, Consultant Paediatrician, HUTH Dr S Raise, GP Prescribing Lead, East Riding Prof M Lind, Vice Chair, Professor of Oncology, HUTH Dr O Ogunbambi, Consultant Rheumatologist, HUTH Dr A Samson, Consultant Infectious Diseases, HUTH
-------------------	--

<b>Apologies</b>	Ms J Goode, Chief Pharmacist, HUTH Luke Storr – Senior Pharmacy Technician, Formulary HUTH
------------------	---

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date	Progress /Date Closed
2022.11.01	<b>Apologies</b>	As Above.					
2022.11.02	<b>Declarations of Interest</b>	None					
2022.11.03	<b>Minutes of the previous meeting</b>	Accepted as true record- add gastro using blueteq to action tracker. Discussion about blueteq and gastro compliance	Gastro to be on EPMA so can see if guidance is being followed	Chair to write to Steve Jessop about EPMA rollout for gastro	AM	12/22	
2022.11.04	<b>Terms of Reference update</b>	Updated in line with role changes and look into patient representative position. Along with time frame for NICE TA approvals.	JM to contact Andy Lockwood to discuss patient representation	Look into patient representative role	JM	12/22	
2022.11.05	<b>Action Tracker</b>	<p><b>Hydroxychloroquine in RA</b> New action: JM to discuss with relevant business managers Update: August 2022 – to escalate via PE&amp;CE Update: September 2022 – escalated via PE&amp;CE</p> <p><b>ARIA forms – Zoledronic acid</b> JM to write trust guidance in conjunction with DME pharmacy team. Dr Aye going to add addition parts to the guidance</p> <p><b>NICE Guidance</b> JM to meet with neurology about TA758. JM discussed with Dr Ming and considering bringing patients back to HUTH. Will apply if needed</p> <p><b>Clinical guidelines – Biologics and small molecules for IBD</b> JM to meet with SS (with surgical team pharmacists) to work on updated guidance and discuss audit- JM and SS not me JG to ensure new pharmacy service to IMIC is set up- JG not present to give update</p>	<p>Ongoing</p> <p>Ongoing</p> <p>Ongoing to add TA to check TA at back of formulary</p> <p>Ongoing</p>	<p>Going to next PE&amp;CE meeting (Dec 22) Additions to be included then re sent to Governance</p> <p>JM to check TA on formulary</p>	<p>JM</p> <p>JM</p>	<p>1/23</p> <p>12/22</p>	

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date	Progress /Date Closed
		<p>New action: Add guidance to agenda when updated New action Sept 2022: Present audit of usetikinumab</p> <p><b>NICE Guidance</b> JM to check with Dr Gordins regarding TA769- Dr Gordins would not use. Dr Gupta would awaiting more correspondence</p> <p><b>NICE guidance</b> JM to contact Dr Jose and Dr Ming re TA808 (fenfluramine) September update: contacted Dr Ming and Dr Jose – JM to confirm NHSE requirements. Dr Ming looking more into drug and will send application in if required. To check back of formulary and add if needed</p> <p><b>Tecovirimat</b> JM to contact Dr Lillie to request application</p> <p><b>New product requests</b> AM to write to applicants</p> <p><b>New product requests</b> LS to update formulary</p> <p><b>Any other Business</b> LS to add NICE compliance in acute trusts to APC agenda</p>	<p>Ongoing</p> <p>Check back of formulary and add if needed</p> <p>Application on agenda</p> <p>Action complete</p> <p>Action complete</p> <p>Action complete</p>	<p>Check formulary</p>	<p>JM</p> <p>JM</p> <p>AM</p> <p>LS</p> <p>LS</p>	<p>12/22</p>	<p>11/22</p> <p>11/22</p> <p>11/22</p> <p>11/22</p>
2022.11.06	<b>New product request form-update</b>	Updated form in line with ICB replacing CCG and funding. Approved to upload on to Pattie	To upload onto Pattie		LS	12/22	
2022.11.07	<b>New Product Requests</b>	<p><b>New Product Requests</b></p> <p>a) Pirotobrutinib (Dr Allsup) Free of charge scheme discussed based on initial clinical trial evidence. Clear unmet clinical need for this group of patients</p> <p>b) Icosapent ethyl (Dr Narayanan) Approved in line with NICE guidance (TA805). To be discussed at APC for classification</p> <p>c) Tecovirimat (Dr Lillie) Approved in line with NHSE guidance</p> <p>d) ITULAZAX® (Dr Khan)</p>	<p>Approved</p> <p>Approved</p> <p>Approved</p> <p>Approved</p>	<p>AM to write to applicants LS to update formulary</p>	<p>AM/LS</p>	<p>11/22</p>	

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date	Progress /Date Closed
		<p>This sublingual immunotherapy for birch pollen allergy which is a licensed product was approved to use instead of OralVac® birch pollen</p> <p><b>ARIA FORMS</b> Nil this month</p>					
2022.11.08	<b>NICE guidance</b>	<p><b>NICE Guidance October 2022</b></p> <ul style="list-style-type: none"> <li>• TA831 Olaparib for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer</li> <li>• TA828 Ozanimod for treating moderately to severely active ulcerative colitis</li> <li>• TA827 Oral azacitidine for maintenance treatment of acute myeloid leukaemia after induction therapy</li> <li>• TA834 SQ HDM SLIT for treating allergic rhinitis and allergic asthma caused by house dust mites (terminated appraisal)</li> <li>• TA835 Fostamatinib for treating refractory chronic immune thrombocytopenia</li> <li>• TA833 Zanubrutinib for treating Waldenstrom's macroglobulinaemia</li> <li>• TA832 Relugolix–estradiol–norethisterone acetate for treating moderate to severe symptoms of uterine fibroids</li> <li>• TA830 Pembrolizumab for adjuvant treatment of renal cell carcinoma</li> <li>• NG226 Osteoarthritis in over 16s: diagnosis and management</li> <li>• TA836 Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy</li> </ul>	<p>Not recommended for this indication</p> <p>Application required</p> <p>On Formulary – check for aria form</p> <p>Terminated appraisal</p> <p>Non-Formulary- Check Aria form On Formulary- check Aria form New Drug- JM to contact Mrs Allen regarding application</p> <p>On Formulary</p> <p>Updated</p> <p>On formulary- Check aria form</p>	<p>No action required</p> <p>Contact Prof Sebastian</p> <p>Contact Mrs Allen</p>			

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date	Progress /Date Closed
		<ul style="list-style-type: none"> <li>TA837 Pembrolizumab for adjuvant treatment of resected stage 2B or 2C melanoma</li> </ul>	On Formulary – to check for Aria				
2022.11.09	<b>MHRA Drug safety update</b>	<ul style="list-style-type: none"> <li><a href="#">October 22</a></li> </ul>	Noted				
2022.11.10	<b>Minutes of the Safe Medication Practice Committee</b>	Nil this month	Complete	No action required			
2022.11.11	<b>Minutes from the Hull and East Riding Prescribing Committee</b>	a) October 2022	Complete	No action required			
2022.11.12	<b>Regional Medicines Optimisation Committee</b>	Nil this month	Noted	No action required			
2022.11.13	<b>Clinical guidelines</b>	Nil this month	Noted	No action required			
2022.11.14	<b>Correspondence received</b>	Nil this month					
2022.11.15	<b>Chairs Approvals</b>	<ul style="list-style-type: none"> <li>Pentazocine feedback</li> <li>Doxycycline IV - (Mr.D.Taylor)</li> </ul>	<ul style="list-style-type: none"> <li>Feedback was positive for the patient. The committee approved further prescribing</li> <li>Committee request application as had three approvals</li> </ul>	No action required to send to APC  Chair to write to applicants			
2022.11.16	<b>Supply problems</b>	<ul style="list-style-type: none"> <li>Remdesivir IV (flow chart attached)</li> <li>Oralvac (dog dander)</li> <li>Novorapid (MSN)</li> </ul>	<ul style="list-style-type: none"> <li>Approved</li> <li>Import alternative approved (Oraltek)</li> <li>Short term supply issue- trurapi to be added to formulary</li> </ul>				

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date	Progress /Date Closed
2022.11.17	Issues to escalate to PE&CE	Nil this month					
2022.11.18	Any Other Business	Nil					
2022.11.19	Date and Time of Next Meeting	8 <sup>th</sup> December 2022 8:15 am via Teams					